explore -WSS

explore

author：comprehensive 2025-08-23 08:57:45 - browse：2149

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： CRISPR gene editing developments we’re watching in 2024

knowledge

Wikipedia

WSS

Why health records don't always know when patients are dead

Violet CEO on training clinicians to promote more inclusive care

How CO2 helps viruses stay alive longer in the air

Can sheer will power keep patients alive in their dying hours?

How to keep neuroscience’s past racism from being its future

Senators tussle over abortion against the backdrop of a presidential campaign

hotspot

explore

focus

Apple is now the first public company to be valued at $3 trillion

BD to buy Edwards patient monitoring unit for $4.2 billion

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare Advantage's lean provider networks lead CMS complaints

DIEP, the 'gold standard' of breast reconstruction, is under threat

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

At least 13 dead in Texas as scorching temps continue

Christmas in the PICU brings some surprising joy

Medicare details structure of new drug price negotiation program

Illumina board agrees to spin off Grail, as divestment plans proceed

focus

Christmas in the PICU brings some surprising joy

ASCO Daily Recap: CAR

Can sheer will power keep patients alive in their dying hours?

FDA approves Moderna’s RSV vaccine, its second licensed product

Violet CEO on training clinicians to promote more inclusive care

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

explore

knowledge

Wikipedia

focus